Kibow Biotech
Kibow Biotech is a privately held Pennsylvania-based biotechnology company that develops clinically studied probiotic and prebiotic supplements—led by Renadyl®—targeting the gut-kidney axis to support chronic kidney disease patients worldwide through DTC e-commerce and country-exclusive distributors.
- Company typePrivate
- Founded1997
- HeadquartersNewtown Square, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Kibow Biotech does
Kibow Biotech is a privately held biotechnology company founded in 1997 by Dr. Natarajan Ranganathan and headquartered in Exton, Pennsylvania. It develops science-based probiotics and prebiotics targeting the gut-kidney axis to support kidney health, with its proprietary platform branded as Enteric Dialysis™. The company serves primarily chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients, at-risk individuals, and healthcare providers (particularly nephrologists) who recommend its products as adjuncts to conventional kidney care.
The core product line is Renadyl®, a patented probiotic supplement delivering 45 billion CFUs per acid-resistant capsule of three proprietary strains—Streptococcus thermophilus KB19, Lactobacillus acidophilus, and Bifidobacterium longum—that metabolize nitrogenous waste compounds (urea, uric acid, creatinine) in the gastrointestinal tract. The portfolio also includes Renadyl® Advanced Multivitamin, a phosphorus- and potassium-free gummy multivitamin launched in November 2025 for CKD/ESRD patients, and Kibow Fortis®, a six-fiber prebiotic supplement supporting digestive and immune health. A separate clinical-stage entity, Kibow Pharmaceuticals LLC, is advancing US-APR2020, a live biotherapeutic product in a Phase IIb global trial for CKD Stage IV following FDA IND approval in April 2021. The technology base is supported by 20+ years of peer-reviewed clinical research, U.S. and India patents, and trademarks for Renadyl®, Enteric Dialysis™, and Kibow Fortis®.
Kibow operates a hybrid go-to-market combining direct-to-consumer e-commerce through shop.kibow.com (offering 90-day supply bundles with free U.S. shipping) with a network of country-exclusive distribution partners across the United States, Canada, the Philippines, Romania, South Korea, Poland, Singapore, India, and Argentina. Revenue is generated through one-time unit-priced supplement sales. The company is founder-controlled, with research historically supported by NIH SBIR grants rather than institutional equity capital, and operates with 11–50 employees.
Kibow Biotech firmographics
Firmographics- Name
- Kibow Biotech
- Legal name
- Kibow Biotech LLC
- Website
- https://kibowbiotech.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kibow Biotech is a privately held Pennsylvania-based biotechnology company that develops clinically studied probiotic and prebiotic supplements—led by Renadyl®—targeting the gut-kidney axis to support chronic kidney disease patients worldwide through DTC e-commerce and country-exclusive distributors.
- Ownership category
- akta.pro rank
Kibow Biotech industry classification
Industry- Product category
- Probiotic Kidney Health Supplements
- NAICS
- Food (Health) Supplement Retailers (456191)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Probiotics & Digestive Health Supplements (CRADAGAF)
- akta.pro secondary industry
- Renal Nutrition & Kidney Dietetics Services (HLAKAHAL)
Keywords
Where Kibow Biotech is headquartered
LocationHeadquarters
- HQ city
- Newtown Square
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kibow Biotech business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Probiotic Dietary Supplements Sales: Kibow Biotech generates revenue through the sale of its probiotic dietary supplement products including Renadyl® (kidney health probiotic), Renadyl® Advanced Multivitamin (kidney-specific gummy multivitamin), and Kibow Fortis® (prebiotic multifiber). Products are sold directly to consumers and through distribution partners globally.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Renadyl® Kidney Health Supplement 90-Day Supply |
Go-to-market motion2 records
Distribution channels8 records
Marketing channels6 records
Kibow Biotech product offering
Product offeringCore offering
Kibow Biotech develops, manufactures, and sells clinically-formulated probiotic and prebiotic dietary supplements that target the gut-kidney axis to support kidney function in patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). The portfolio centers on Renadyl®, a patented probiotic supplement delivering 45 billion CFUs of proprietary bacterial strains that metabolize nitrogenous waste (urea, uric acid, creatinine) in the gastrointestinal tract, complemented by Renadyl® Advanced Multivitamin (kidney-specific gummy) and Kibow Fortis® (prebiotic multifiber).
Product overview
Kibow Biotech offers a portfolio of scientifically-formulated probiotic and prebiotic solutions targeting the gut-kidney axis to support kidney health. The core product is Renadyl®, a patented probiotic supplement containing 45 billion CFUs of three proprietary strains that metabolize nitrogenous toxins. This is complemented by Renadyl® Advanced Multivitamin (the first gummy multivitamin for kidney health patients, avoiding phosphorus and potassium) and Kibow Fortis®, a multi-fiber prebiotic supplement designed to support digestive and immune health. All products work together to address different aspects of kidney health and overall wellness through microbiome modulation.
Differentiator
Problem solved
Functional benefit
Brands
- Renadyl: The #1 nephrologist-recommended probiotic dietary supplement clinically proven to improve or maintain kidney function. Contains 45 billion CFUs of three proprietary probiotic strains.
- Renadyl Advanced Multivitamin
- Kibow Fortis
- US-APR2020
- Enteric Dialysis
Products and services
- Renadyl® Probiotic Kidney Health Supplement Patented probiotic health supplement clinically proven to improve or maintain kidney function. Each acid-resistant capsule delivers 45 billion CFUs of three proprietary strains (Streptococcus thermophilus KB19, Lactobacillus acidophilus, Bifidobacterium longum) that metabolize nitrogenous toxins such as urea, uric acid, and creatinine within the gastrointestinal tract. Positioned as the #1 nephrologist-recommended probiotic dietary kidney supplement, intended for CKD and ESRD patients.
- Renadyl® Advanced Multivitamin First and only gummy multivitamin specially formulated for people managing CKD or ESRD. Complements Renadyl probiotic therapy by providing targeted nutritional support while avoiding phosphorus and potassium, which are restricted in kidney patients' diets.
- Kibow Fortis® Prebiotic Multifiber Scientifically formulated prebiotic multi-fiber dietary supplement designed to support digestive health and intestinal flora balance. Contains six prebiotic fibers to nourish beneficial gut bacteria while supporting satiety, lipid balance, and immune health for kidney patients and the broader at-risk population.
Quantifiable outcome
- 45 billion CFUs per capsule
- +4 more outcomes
Companies that use Kibow Biotech
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Kibow Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Kibow Biotech partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and strategic.
- Kibow Pharmaceuticals LLCcorePhase 2/3 clinical-stage company focused on developing novel live biotherapeutic products (LBP) for CKD patients. First clinical product US-APR2020 is in Phase IIb multi-site global clinical trial recruiting CKD stage 4 subjects.
- Centaur PharmaceuticalscoreStrategic alliance announced on World Kidney Day 2018 to market Renadyl in India. Given the high prevalence of Chronic Kidney Illness in India (17.2% and rising), this partnership addresses a significant market opportunity for Kibow's patented and clinically-tested kidney health supplement.
- Dega International Pharma Corp.coreExclusive distributor for Renadyl in the Philippines (PHL), enabling access to the Southeast Asian market for Kibow's kidney health products.
- Gelda ScientificcoreCanadian distributor for Kibow products, providing access to the Canadian market for Renadyl and other kidney health supplements.
- Healthy Medical SRLcoreRomanian distributor for Renadyl and Kibow product line, enabling market access in Eastern Europe.
- Tailored ProbiocoreSouth Korean distribution partner for Kibow's probiotic supplements, expanding presence in the Asian market.
- RebonumcorePolish distributor for Kibow products, enabling access to the European market.
- Z-Wave Lifestyle Pte Ltd.coreSingapore-based distributor for Kibow's kidney health products, providing market access in Singapore.
- Thomas Jefferson UniversitystrategicAcademic research partner for open-label dose escalation study of Kibow Biotics (Renadyl) in CKD Stage III and IV patients, conducted May 2011 to December 2012.
- SUNY-Downstate Medical CenterstrategicAcademic partner for double-blind, randomized, placebo-controlled crossover study in CKD patients on dialysis (Renadyl), conducted April 2011 to December 2012. Led by Dr. Eli A. Friedman.
- Ghent University (Belgium)strategicResearch collaboration for in vitro studies using Simulated Human Intestinal Microbial Ecosystem (SHIME) biochemical reactor to study probiotic formulations for uremia therapy.
- Indiana University School of MedicinestrategicCollaboration for preclinical studies in 5/6th nephrectomized minipig models of chronic renal failure, studying probiotic bacteriotherapy applications.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Kibow Biotech competitors and assessment
Company assessmentDirect peers
- BioGaia: Swedish probiotics company developing clinically documented probiotic strains for specific health conditions, with a similar model of pairing proprietary strains with health-condition-specific branding. Most comparable as a clinically-oriented probiotic supplement company with B2B and B2C channels.
- Culturelle (i-Health / Chr. Hansen): One of the largest clinically-backed probiotic supplement brands in the US, sold through mass retail and pharmacy channels. Competes with Kibow in the digestive/gut-health probiotic shelf space and shares the clinical-credibility positioning model.
- Seed Health: Premium DTC probiotic brand built on proprietary strain science and published clinical research. Comparable to Kibow's premium clinical-credibility positioning and direct-to-consumer e-commerce distribution model.
- Ganeden (Kerry Group): Probiotic ingredient technology company (GanedenBC30 / Bacillus coagulans GBI-30) that licenses proprietary strains into supplements and functional foods. Comparable to Kibow's proprietary-strain licensing and B2B ingredient strategy.
Emerging players
- Pendulum Therapeutics: Microbiome company developing probiotic and prebiotic products targeting metabolic conditions, with a clinical evidence-driven DTC model. Comparable to Kibow as a science-forward microbiome company targeting chronic disease consumers.
- Ardelyx: Late-stage biopharmaceutical company developing therapies for kidney disease (e.g., tenapanor for hyperphosphatemia in CKD). Comparable to Kibow as a CKD-focused therapeutics company targeting nitrogenous waste management.
Broad incumbents
- Yakult Honsha: Global probiotic dairy beverage company built around the proprietary Lactobacillus casei Shirota strain with decades of clinical research. Comparable as a scaled, science-led probiotic brand targeting gut health consumers globally.
- Danone (Activia / Actimel): Multinational food giant with the largest probiotic food and beverage portfolio globally. Comparable to Kibow as a scaled probiotic brand operator, though far broader in scope and distribution.
- Chr. Hansen: Global bioscience company producing probiotic cultures, enzymes, and microbial solutions for supplements, dairy, and infant nutrition. Comparable to Kibow on the probiotic strain science and ingredient side of the business.
- AstraZeneca: Multinational pharmaceutical company whose drug Farxiga (dapagliflozin) is approved for CKD. Comparable to Kibow as a player addressing the CKD market, though at scale and as a guideline-directed prescription therapy rather than an adjunct supplement.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Kibow Biotech social profiles
Digital presenceKibow Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kibow Biotech leadership team
Management profileNumber of profiles
Profiles1 record
Kibow Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kibow Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kibow Biotech
What does Kibow Biotech do?
Kibow Biotech develops, manufactures, and sells clinically-formulated probiotic and prebiotic dietary supplements that target the gut-kidney axis to support kidney function in patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). The portfolio centers on Renadyl®, a patented probiotic supplement delivering 45 billion CFUs of proprietary bacterial strains that metabolize nitrogenous waste (urea, uric acid, creatinine) in the gastrointestinal tract, complemented by Renadyl® Advanced Multivitamin (kidney-specific gummy) and Kibow Fortis® (prebiotic multifiber).
Is Kibow Biotech a public or private company?
Kibow Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Kibow Biotech founded?
Kibow Biotech was founded in 1997. It employs 11 to 50 people.
Where is Kibow Biotech based?
Kibow Biotech is headquartered in Newtown Square, United States, in the North America region.
How does Kibow Biotech make money?
One revenue line is on record: probiotic Dietary Supplements Sales.
Who are Kibow Biotech's main competitors?
Direct peers on record are BioGaia, Culturelle (i-Health / Chr. Hansen), Seed Health and Ganeden (Kerry Group). Emerging players are Pendulum Therapeutics and Ardelyx. Broad incumbents are Yakult Honsha, Danone (Activia / Actimel), Chr. Hansen and AstraZeneca.
Does Kibow Biotech have an API?
No public API is recorded for Kibow Biotech.
What industry is Kibow Biotech in?
Kibow Biotech's product category is Probiotic Kidney Health Supplements. Its primary akta.pro industry code is CRADAGAF, Probiotics & Digestive Health Supplements, with a secondary code of HLAKAHAL, Renal Nutrition & Kidney Dietetics Services. Its NAICS code is 456191 and its SIC code is 2834.